면책조항: 이것은 법률 자문이 아닙니다. 법률과 판례는 변경됩니다. 귀하의 특정 상황에 대해 항상 자격을 갖춘 변호사와 상담하십시오.

모든 판례
Intellectual Property
Supreme Court
2017

Actavis UK Ltd v Eli Lilly & Co

[2017] UKSC 48

판결 이유

Patent infringement should be assessed in two stages: (1) does the variant infringe on a normal (purposive) interpretation of the claim? (2) if not, does the variant nonetheless infringe because it varies from the invention in a way that is immaterial? The reformulated Improver/Protocol questions apply to the second stage.

사실관계

Eli Lilly held a patent for pemetrexed disodium, a cancer treatment. Actavis sought to market a product using pemetrexed diacid, a different salt form.

판결 요약

The Supreme Court held the Actavis product infringed. Lord Neuberger reformulated the approach to equivalents, holding that a two-stage test applies and that the doctrine of equivalents is part of English patent law.

주요 인용문

"The problem of infringement must be approached by addressing two issues, each relating to the scope of the monopoly: (i) does the variant infringe any of the claims as a matter of normal interpretation? (ii) if not, does the variant nonetheless infringe because it varies from the invention in a way or ways which is or are immaterial?"

Lord Neuberger

후속 처리

Good law

The leading authority on patent infringement by equivalents in UK law.